Allergan Signs an Exclusive Option and License Agreement with Exicure to Discover and Develop SNA-based Therapies for Hair Loss Disorders

Shots:

• Exicure to receive $25M upfront, up to $97.5/program development & regulatory milestones, ~$265/program commercial milestones, royalties on global sales of therapies developed under the collaboration and will conduct discovery and development in two programs for hair loss disorders like androgenetic alopecia
• Allergan to get exclusive access and options to license SNA-based therapies developed under the collaboration. Post exercises an option, Allergan will be responsible for clinical development and commercialization of licensed therapies
• Exicure’s SNA technology unlocks the potential of therapeutic oligonucleotides in a wide range of cells and tissues. Exciure’s lead program is in P-Ib/II study for patients with advanced solid tumors

Click here to­ read full press release/ article | Ref: Exicure | Image: Waco Tribune